PRLD Quote, Financials, Valuation and Earnings

Immunome, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of -1080.87%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Immunome, Inc.'s return on equity of -90.08%.

Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 63.27%. On the other hand Immunome, Inc. has an analysts' consensus of $34.25 which suggests that it could grow by 57.76%. Given that Prelude Therapeutics, Inc. has higher upside potential than Immunome, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Immunome, Inc..

Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Immunome, Inc. has a beta of 2.175, suggesting its more volatile than the S&P 500 by 117.492%.

Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunome, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Immunome, Inc. pays out -- of its earnings as a dividend.

Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Immunome, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is higher than Immunome, Inc.'s net income of -$57.5M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunome, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 16.52x versus 177.80x for Immunome, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Incyte Corp. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 31.05%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Incyte Corp.'s return on equity of 31.1%.

Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 63.27%. On the other hand Incyte Corp. has an analysts' consensus of $100.10 which suggests that it could fall by -0.02%. Given that Prelude Therapeutics, Inc. has higher upside potential than Incyte Corp., analysts believe Prelude Therapeutics, Inc. is more attractive than Incyte Corp..

Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.810, suggesting its less volatile than the S&P 500 by 18.956%.

Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.

Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Incyte Corp.'s net income of $424.2M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 16.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 16.52x versus 4.14x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 13.19%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 63.27%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 507.74%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..

Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 16.52x versus 2.30x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Relay Therapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of -10395.13%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Relay Therapeutics, Inc.'s return on equity of -41.21%.

Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 63.27%. On the other hand Relay Therapeutics, Inc. has an analysts' consensus of $14.60 which suggests that it could grow by 70.56%. Given that Relay Therapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..

Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Relay Therapeutics, Inc. has a beta of 1.501, suggesting its more volatile than the S&P 500 by 50.076%.

Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relay Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Relay Therapeutics, Inc. pays out -- of its earnings as a dividend.

Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Relay Therapeutics, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is higher than Relay Therapeutics, Inc.'s net income of -$74.1M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Relay Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 16.52x versus 174.21x for Relay Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.